SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.70-2.2%3:41 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (3694)5/8/2001 9:37:22 AM
From: Mark Bong   of 52153
 
Harold, if it is the same molecule as stated by many including Ares Serono, then the three times a week dosage does have a major impact on efficacy. There is another question. What impact does it have on the patient? Three times a week seems like a tough regimen. Would the higher dosage cause long-term safety issues? How would the patient do on a prolonged basis? For sure the data looks compelling, but I feel that there are still many questions to be answered.

In addition, Serono has used pretty severe tactics to brow beat the FDA, including using Congressional reps to push them. I know that civil servants don’t like this, and I would suggest that the FDA would demand a great deal of proof before this one gets approval. As for Biogen, their future is in Amevive and ELAN, and they had better dig up a few more good licensing opportunities.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News